92,394 Shares in Corcept Therapeutics Incorporated $CORT Bought by Ieq Capital LLC

Ieq Capital LLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 92,394 shares of the biotechnology company’s stock, valued at approximately $8,034,000. Ieq Capital LLC owned about 0.09% of Corcept Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Pathstone Holdings LLC lifted its holdings in Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after buying an additional 144 shares during the last quarter. State of Wyoming increased its holdings in shares of Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares during the last quarter. Gould Capital LLC increased its holdings in shares of Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Corcept Therapeutics by 3.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 247 shares in the last quarter. Finally, Evergreen Capital Management LLC raised its position in shares of Corcept Therapeutics by 3.0% during the 4th quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 248 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright boosted their target price on Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a report on Monday, July 27th. Weiss Ratings upgraded shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday. Finally, Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.17.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks sharply raised long-term earnings forecasts. The firm increased its FY2026 EPS estimate to $1.02 from $0.38, FY2027 to $1.91 from $1.25, and FY2028 to $4.07 from $3.14. Quarterly estimates were also raised, including Q1 2027 to $0.11 from a projected loss of $0.17 and Q2 2028 to $1.17 from $0.69. These revisions signal expectations for accelerating profitability.
• Positive Sentiment: Recent operating results provide support for the bullish outlook. Corcept’s latest reported quarter produced $0.36 in EPS versus the $0.02 consensus estimate, while revenue of $256.15 million exceeded expectations of $221.15 million and grew 31.7% year over year.
• Positive Sentiment: Analyst sentiment and price targets remain constructive. Recent coverage includes Buy or Overweight ratings and price targets ranging from $150 to $165, while the reported consensus rating is “Moderate Buy” with a $138.17 target. An investment analysis also argued that the launch of Lifyorli and continued Korlym growth could drive revenue growth, margin expansion and further EPS upside. Like The Knicks, Corcept Rebounded And Is Crushing It
• Neutral Sentiment: Zacks maintained a “Hold” rating. The improved earnings estimates are encouraging, but the unchanged rating suggests the analyst views the stock’s substantial rally and high valuation as partly reflected in the price.
• Negative Sentiment: Director David Mahoney sold 103,606 shares for approximately $12.25 million. The transaction reduced his ownership by 8.37%, although he still retained more than 1.13 million shares. The sale could create short-term sentiment pressure, but it does not necessarily indicate a change in the company’s fundamentals. Insider Selling: Corcept Therapeutics Director Sells Stock

Corcept Therapeutics Price Performance

NASDAQ CORT opened at $122.25 on Monday. The firm has a market cap of $13.22 billion, a P/E ratio of 291.08 and a beta of 0.45. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $123.44. The business’s 50-day moving average price is $97.39 and its 200 day moving average price is $64.76.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same period in the prior year, the business earned $0.29 EPS. The firm’s revenue was up 31.7% compared to the same quarter last year. As a group, analysts anticipate that Corcept Therapeutics Incorporated will post 1.77 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Atabak Mokari sold 80,000 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $114.71, for a total transaction of $9,176,800.00. Following the completion of the sale, the chief financial officer directly owned 16,130 shares of the company’s stock, valued at $1,850,272.30. This trade represents a 83.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total transaction of $1,862,600.00. Following the completion of the transaction, the insider owned 3,985 shares in the company, valued at approximately $371,123.05. This trade represents a 83.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 520,146 shares of company stock worth $48,903,764. 20.70% of the stock is currently owned by company insiders.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.